Compare AAME & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | NEPH |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 40.1M |
| IPO Year | 1995 | 2004 |
| Metric | AAME | NEPH |
|---|---|---|
| Price | $1.75 | $3.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 14.8K | 9.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | ★ 0.22 | 0.01 |
| Revenue | ★ $188,227,000.00 | $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ $7.64 | $327.00 |
| Revenue Growth | 0.77 | ★ 32.67 |
| 52 Week Low | $1.59 | $2.66 |
| 52 Week High | $3.71 | $6.42 |
| Indicator | AAME | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 57.34 |
| Support Level | $1.59 | $2.77 |
| Resistance Level | $3.16 | $3.79 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 43.33 | 91.84 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.